insurtech

Lemonade (LMND) Stock Soars on Q3 Beat – Is Insurtech Growth Sustainable?

Recent News: Q3 Results and Market Reaction On Nov. 5, 2025 after market-close, Lemonade released its Q3 financials, and the stock surged. Both press coverage and company statements highlighted robust top-line growth and improving loss metrics. For example, Investing.com reported revenue +42% YOY to $194.5M (well above the ~$184–185M expected) and a narrower-than-forecast loss of $0.51 per share au.investing.com. It noted in-force premium (IFP) up 30% YOY to $1.16B – an eighth consecutive quarter of accelerating growth au.investing.com. The CEO, Daniel Schreiber, said: “In Q3, we continued both our growth acceleration — crossing 30% IFP growth ahead of schedule — and

5 November 2025

Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Oscar Health (OSCR) Stock Skyrockets on ACA Hopes and Tech-Driven Growth – Can the Insurtech Finally Turn a Profit?

Financial Performance & Q2 2025 Results Oscar Health’s Q2 2025 results showed rapidly growing revenue but steep losses. Revenue was $2.86 billion, up ~29% from $2.22 billion a year earlier beckerspayer.com. This growth stemmed largely from higher membership – Oscar served over 2.0 million members by mid-2025 (28% growth YoY) beckerspayer.com. However, costs ballooned: Oscar’s medical loss ratio (MLR) jumped to 91.1% in Q2 2025 (vs. 79.0% in Q2 2024) beckerspayer.com. The company attributed this to an increase in average member morbidity and higher-than-expected risk in the ACA population. The operating result was a $230 million loss (vs. $67.8M operating income in Q2 2024),

6 October 2025

Affordable Care Act · Health Insurance · Insurtech · NYSE:OSCR · Stock Analysis · Technology Growth